Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has recalled a batch of its generic Parkinson’s combination drug treatment carbidopa/levodopa because of concern that it may contain too much active pharmaceutical ingredient.
The company said that the Class II recall involved 3, 881 bottles of 25 or 100mg carbidopa/levodopa. Teva added that stability testing found that the product might be “superpotent.” The voluntary recall is for the entire US.
Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
A class II recall as defined by the US Food and Drug Administration (FDA) means that use of a drug could cause temporary damage to health.
Published by Globes [online], Israel business news – www.globes-online.com – on August 28, 2014
